JP2014512409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512409A5 JP2014512409A5 JP2014508125A JP2014508125A JP2014512409A5 JP 2014512409 A5 JP2014512409 A5 JP 2014512409A5 JP 2014508125 A JP2014508125 A JP 2014508125A JP 2014508125 A JP2014508125 A JP 2014508125A JP 2014512409 A5 JP2014512409 A5 JP 2014512409A5
- Authority
- JP
- Japan
- Prior art keywords
- protocell
- composition according
- composition
- seq
- protocells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000592 Artificial Cell Substances 0.000 claims description 135
- 239000000203 mixture Substances 0.000 claims description 68
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 30
- 108010033040 Histones Proteins 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 23
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 22
- 239000000232 Lipid Bilayer Substances 0.000 claims description 18
- 235000012000 cholesterol Nutrition 0.000 claims description 15
- 239000004055 small Interfering RNA Substances 0.000 claims description 13
- 108020004459 Small interfering RNA Proteins 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 10
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 230000030648 nucleus localization Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000005090 green fluorescent protein Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- 108010052763 H5WYG peptide Proteins 0.000 claims description 2
- 102100039869 Histone H2B type F-S Human genes 0.000 claims description 2
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229910000077 silane Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000013626 chemical specie Substances 0.000 claims 5
- 239000003443 antiviral agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 150000004706 metal oxides Chemical group 0.000 claims 4
- 231100000654 protein toxin Toxicity 0.000 claims 4
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 claims 3
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 2
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 claims 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 claims 1
- OBPOCAKICKFMGM-PGUFJCEWSA-N 2-[di(hexadecanoyl)amino]ethyl [(2R)-2,3-dihydroxypropyl] hydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCC)=O OBPOCAKICKFMGM-PGUFJCEWSA-N 0.000 claims 1
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 108010054624 red fluorescent protein Proteins 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000006208 topical dosage form Substances 0.000 claims 1
- 239000006211 transdermal dosage form Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 49
- 239000002105 nanoparticle Substances 0.000 description 25
- 239000000377 silicon dioxide Substances 0.000 description 24
- 239000012099 Alexa Fluor family Substances 0.000 description 22
- 210000003494 hepatocyte Anatomy 0.000 description 20
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 12
- 101001045123 Homo sapiens Hyccin Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000002479 lipoplex Substances 0.000 description 10
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 9
- 102000006947 Histones Human genes 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000008178 Cyclin B1 Human genes 0.000 description 7
- 108010060385 Cyclin B1 Proteins 0.000 description 7
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 7
- 210000003855 cell nucleus Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical group CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000002429 nitrogen sorption measurement Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 3
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000001998 small-angle neutron scattering Methods 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 101150060955 RAB11A gene Proteins 0.000 description 2
- 101150030875 RAB7A gene Proteins 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 210000004492 nuclear pore Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000000733 zeta-potential measurement Methods 0.000 description 2
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241001083548 Anemone Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710135281 DNA polymerase III PolC-type Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000001282 organosilanes Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- AYEFIAVHMUFQPZ-UHFFFAOYSA-N propane-1,2-diol;prop-2-enoic acid Chemical compound CC(O)CO.OC(=O)C=C AYEFIAVHMUFQPZ-UHFFFAOYSA-N 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479847P | 2011-04-28 | 2011-04-28 | |
| US61/479,847 | 2011-04-28 | ||
| PCT/US2012/035529 WO2012149376A2 (en) | 2011-04-28 | 2012-04-27 | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014512409A JP2014512409A (ja) | 2014-05-22 |
| JP2014512409A5 true JP2014512409A5 (enExample) | 2015-06-18 |
Family
ID=47073093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508125A Pending JP2014512409A (ja) | 2011-04-28 | 2012-04-27 | 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9579283B2 (enExample) |
| EP (1) | EP2701686A4 (enExample) |
| JP (1) | JP2014512409A (enExample) |
| CN (1) | CN103687590A (enExample) |
| AU (1) | AU2012249474A1 (enExample) |
| CA (1) | CA2834365A1 (enExample) |
| WO (1) | WO2012149376A2 (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664944C (en) * | 2006-09-28 | 2016-06-14 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
| US8992984B1 (en) | 2009-10-21 | 2015-03-31 | Stc.Unm | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| CN103687590A (zh) | 2011-04-28 | 2014-03-26 | Stc·Unm公司 | 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法 |
| CN107115314B (zh) * | 2011-06-02 | 2022-04-29 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
| WO2013012891A1 (en) | 2011-07-19 | 2013-01-24 | Stc. Unm | Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| US20150272885A1 (en) * | 2011-10-14 | 2015-10-01 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013103614A1 (en) * | 2011-12-30 | 2013-07-11 | Stc.Unm | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9273305B1 (en) | 2012-04-25 | 2016-03-01 | Sandia Corporation | Cell-based composite materials with programmed structures and functions |
| US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| WO2014110591A1 (en) | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| WO2014138278A1 (en) | 2013-03-05 | 2014-09-12 | The Regents Of The University Of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| US20140271815A1 (en) * | 2013-03-15 | 2014-09-18 | Aryo Sorayya | Heat-and freeze-stable vaccines and methods of making and using same |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9603799B2 (en) | 2013-03-15 | 2017-03-28 | Htd Biosystems Inc. | Liposomal vaccine adjuvants and methods of making and using same |
| WO2014165617A1 (en) * | 2013-04-02 | 2014-10-09 | Stc.Unm | Mesoporous alum nanoparticles as universal platform for antigen adsorption, presentation, and delivery |
| CN103989631A (zh) * | 2013-04-15 | 2014-08-20 | 中国人民解放军第二军医大学 | 萝卜硫素制剂及其制备方法和应用 |
| CN103990130A (zh) * | 2013-06-24 | 2014-08-20 | 中国人民解放军第二军医大学 | 介孔二氧化硅纳米制剂及其制备方法和应用 |
| WO2014210448A1 (en) | 2013-06-27 | 2014-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
| EP3046547A4 (en) * | 2013-09-18 | 2017-05-24 | Stc.Unm | Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| WO2016013751A1 (ko) | 2014-07-22 | 2016-01-28 | 주식회사 레모넥스 | 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도 |
| US20160090603A1 (en) * | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
| CN104667290A (zh) * | 2014-10-25 | 2015-06-03 | 中国科学技术大学 | 一种靶向肽修饰的金纳米颗粒及其制备方法和其作为四价铂前体药物载体的应用 |
| WO2016205515A1 (en) * | 2015-06-17 | 2016-12-22 | The Curators Of The University Of Missouri | GOLD NANOROD BASED DIAGNOSTIC AGENT FOR DETECTION AND QUANTIFICATION OF c-MET (HGF) RECEPTORS |
| WO2017008059A1 (en) * | 2015-07-09 | 2017-01-12 | The Regents Of The University Of California | Fusogenic liposome-coated porous silicon nanoparticles |
| LU92784B1 (en) | 2015-07-22 | 2017-01-31 | Luxembourg Inst Of Science And Tech (List) | Negatively charged self-assembling supported lipid bilayer on mesoporous silica nanoparticles, method of synthesis and use as a nanovector |
| LU92783B1 (en) * | 2015-07-22 | 2017-01-31 | Luxembourg Inst Of Science And Tech (List) | Highly aminated self-assembling fuctionalized Mesoporous Silicia Nanoparticles and methods of synthesis |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| JP2017038539A (ja) * | 2015-08-18 | 2017-02-23 | 日本電信電話株式会社 | 脂質二分子膜基板 |
| US20190262469A1 (en) * | 2015-09-04 | 2019-08-29 | C. Jeffrey Brinker | Protocells to treat microbial infection and for synergistic delivery |
| WO2017041033A1 (en) * | 2015-09-04 | 2017-03-09 | Brinker C Jeffrey | Mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles for biomedical applications |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| US10016422B2 (en) * | 2015-09-30 | 2018-07-10 | Oregon State University | Nanocarrier drug delivery platform |
| PL3365020T3 (pl) * | 2015-10-22 | 2020-03-31 | Delsitech Oy | Preparat depot kompozytu hydrożelowego |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| CN105456198B (zh) * | 2015-12-25 | 2017-04-26 | 正大天晴药业集团股份有限公司 | 一种荷载恩替卡韦介孔二氧化硅纳米粒及其制备方法 |
| WO2017117275A1 (en) * | 2015-12-31 | 2017-07-06 | City Of Hope | Silica nanoparticle with platinum anti-cancer agent |
| WO2017120504A1 (en) | 2016-01-08 | 2017-07-13 | Durfee Paul N | Osteotropic nanoparticles for prevention or treatment of bone metastases |
| WO2017120537A1 (en) | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
| JP2019512477A (ja) * | 2016-03-16 | 2019-05-16 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断 |
| CN109843301B (zh) * | 2016-04-14 | 2022-05-27 | 斯宾纳克生物科学公司 | 用于递送治疗剂的含金属硅酸盐的多孔硅材料 |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| US10663450B2 (en) * | 2016-06-15 | 2020-05-26 | The University Of Chicago | Amorphous, porous silicon materials and related methods |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US20190336532A1 (en) * | 2016-12-21 | 2019-11-07 | Fred Hutchinson Cancer Research Center | Scaffolds to treat solid tumor cells and escape variants |
| US10874768B2 (en) * | 2017-01-20 | 2020-12-29 | Covidien Lp | Drug eluting medical device |
| JP6883354B2 (ja) | 2017-02-06 | 2021-06-09 | レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． | 生理活性物質送達体 |
| US11344629B2 (en) | 2017-03-01 | 2022-05-31 | Charles Jeffrey Brinker | Active targeting of cells by monosized protocells |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| WO2018187287A1 (en) * | 2017-04-03 | 2018-10-11 | Charles Jeffrey Brinker | Porous nanoparticle-supported lipid bilayer delivery of transcriptional gene modulators |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| US11576872B2 (en) * | 2017-05-08 | 2023-02-14 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| US11007516B1 (en) | 2017-06-19 | 2021-05-18 | National Technology & Engineering Solutions Of Sandia, Llc | Tunable metal-organic framework compositions and methods thereof |
| CN110996911B (zh) * | 2017-06-26 | 2023-01-17 | 福多兹制药公司 | 阿瑞匹坦的纳米微脂囊配制品及其方法和应用 |
| JP6865491B2 (ja) * | 2017-07-25 | 2021-04-28 | レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． | 血管内生理活性物質送達用組成物 |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| KR102152348B1 (ko) | 2017-09-05 | 2020-09-08 | 주식회사 레모넥스 | 세포 운명 조절용 조성물 |
| WO2019057113A1 (en) * | 2017-09-22 | 2019-03-28 | Jingjie Ptm Biolab (Hangzhou) Co., Ltd. | CAPECITABINE POLYMER-LIPID HYBRID NANOPARTICLES USING MICROMELIN AND AMPHIPHILIC CAPECITABINE PROPERTIES |
| US10933027B1 (en) | 2017-09-25 | 2021-03-02 | National Technology & Engineering Solutions Of Sandia, Llc | Expanded pore particles and delivery methods thereof |
| EP3735250A4 (en) | 2018-01-01 | 2022-04-13 | The Regents Of The University Of California | UPSCALE SYNTHESIS OF SILICASOME NANOCARRIAGES |
| US20200405650A1 (en) * | 2018-02-28 | 2020-12-31 | Achraf Noureddine | Starry mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles |
| CN112292594B (zh) * | 2018-05-08 | 2024-06-25 | 耶鲁大学 | 蛋白质捕获膜及其使用方法 |
| US11045554B1 (en) * | 2018-06-22 | 2021-06-29 | National Technology & Engineering Solutions Of Sandia, Llc | Lipid-coated particles for treating viral infections |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| CN108938595B (zh) * | 2018-07-15 | 2021-09-14 | 河南工业大学 | 一种共载siRNA与化疗药物的阳离子脂质-介孔硅复合纳米载体的制备方法 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US12252708B2 (en) | 2018-09-24 | 2025-03-18 | Unm Rainforest Innovations | Living mammalian cells modified with functional modular nanoparticles |
| US20230048166A1 (en) * | 2018-11-14 | 2023-02-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| KR20210131991A (ko) | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 구획-특이적 카고 전달을 위한 조성물 및 방법 |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| WO2020176716A1 (en) | 2019-02-28 | 2020-09-03 | Brinker C Jeffrey | Modular metal–organic polyhedra superassembly compositions |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| CN110120249B (zh) * | 2019-05-23 | 2023-01-06 | 复旦大学 | 通过靶向调控动力学路径构造靶向构造目标结构的方法 |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CN111529504B (zh) * | 2020-03-25 | 2023-01-10 | 西安组织工程与再生医学研究所 | 功能性嵌合凋亡小体及其制备方法和应用 |
| CN111529505B (zh) * | 2020-03-25 | 2023-04-11 | 西安组织工程与再生医学研究所 | 功能性嵌合凋亡小体及其制备方法和应用 |
| US11433121B1 (en) | 2020-04-03 | 2022-09-06 | National Technology & Engineering Solutions Of Sandia, Llc | Lipid composition for the delivery of therapeutic cargos |
| CN111588704B (zh) * | 2020-07-01 | 2023-04-11 | 西安组织工程与再生医学研究所 | 靶向响应性释放系统及其制备方法和应用 |
| CN111991558B (zh) * | 2020-08-28 | 2022-08-09 | 安徽贝克生物制药有限公司 | 一种抗逆转录病毒药物组合物及其制备方法 |
| CN112168977A (zh) * | 2020-10-27 | 2021-01-05 | 西南大学 | 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用 |
| CN112480212A (zh) * | 2020-12-17 | 2021-03-12 | 中国药科大学 | 靶向肝细胞生长因子的高亲和肽及其应用 |
| JP2024532963A (ja) | 2021-04-08 | 2024-09-11 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８特異的抗体コンストラクト及びその組成物 |
| CN117460542A (zh) * | 2021-06-11 | 2024-01-26 | 纳米智能生物医学工程有限公司 | 包含用于将寡核苷酸递送至靶细胞内的肽-脂质缀合物的纳米颗粒以及包含其的药物组合物 |
| US20230321032A1 (en) * | 2022-04-06 | 2023-10-12 | University Of Kentucky Research Foundation | Functionalized mesoporous silica nanoparticles for treatment of periodontal disease |
| US12194458B2 (en) * | 2022-08-16 | 2025-01-14 | Nicole Shamayev | Device and method of portable drug testing |
| US12098200B1 (en) | 2022-10-12 | 2024-09-24 | National Technology & Engineering Solutions Of Sandia, Llc | Brain-targeting single domain antibodies and purification methods |
| WO2024182425A1 (en) * | 2023-02-27 | 2024-09-06 | Noureddine Achraf | Compositions and methods for treating metabolic diseases/disorders |
| US12629392B2 (en) | 2023-04-19 | 2026-05-19 | Imam Abdulrahman Bin Faisal University | Method of treating covid-19 infection using superparamagnetic iron oxide nanoparticle |
| CN120504733A (zh) * | 2025-03-28 | 2025-08-19 | 江南大学 | 一种用于骨折修复的生物合成类i型胶原蛋白水凝胶及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5277913A (en) | 1991-09-09 | 1994-01-11 | Thompson David H | Liposomal delivery system with photoactivatable triggered release |
| US5820879A (en) | 1993-02-12 | 1998-10-13 | Access Pharmaceuticals, Inc. | Method of delivering a lipid-coated condensed-phase microparticle composition |
| JP2950520B2 (ja) | 1993-04-02 | 1999-09-20 | アンティキャンサー インコーポレーテド | 毛胞に有益な配合物を送達する方法 |
| US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| ES2318906T3 (es) * | 1998-11-13 | 2009-05-01 | Cyclacel Limited | Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia. |
| WO2000076556A2 (en) | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| GB0104259D0 (en) * | 2001-02-21 | 2001-04-11 | Smithkline Beecham Biolog | Novel compounds |
| WO2003016040A1 (en) | 2001-04-16 | 2003-02-27 | The Regents Of The University Of California | Membrane mimetic architectures on nanoporous materials |
| WO2003055469A1 (en) | 2001-12-21 | 2003-07-10 | Celator Technologies Inc. | Improved polymer-lipid delivery vehicles |
| US20040005352A1 (en) | 2002-04-16 | 2004-01-08 | Lopez Gabriel P. | Biologically functionalized porous microspheres |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| US7563451B2 (en) | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
| US8871272B2 (en) | 2005-02-14 | 2014-10-28 | Australian Nuclear Science & Technology Organisation | Layered nanoparticles |
| US7514267B1 (en) | 2005-08-19 | 2009-04-07 | Stcunm | Detection systems utilizing supported lipid bilayers |
| AU2006315825A1 (en) | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
| US20080160313A1 (en) * | 2006-04-26 | 2008-07-03 | Gabriel Lopez | Lipid bilayers on nanotextured solid surfaces |
| CA2657946A1 (en) | 2006-06-09 | 2007-12-13 | Protox Therapeutics Incorporated | Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease |
| US9803189B2 (en) | 2006-08-23 | 2017-10-31 | Stc.Unm | Virus-like platform for rapid vaccine discovery |
| WO2008073856A2 (en) | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| US20080279764A1 (en) | 2007-03-09 | 2008-11-13 | Anthony Manganaro | Method and composition for treating cancer |
| US9993437B2 (en) | 2007-12-06 | 2018-06-12 | The Regents Of The University Of California | Mesoporous silica nanoparticles for biomedical applications |
| WO2009091531A2 (en) | 2008-01-16 | 2009-07-23 | The General Hospital Corporation | Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| CN101658533A (zh) | 2008-08-29 | 2010-03-03 | 首都医科大学宣武医院 | 抗肿瘤药物的干细胞递送 |
| WO2010048572A1 (en) | 2008-10-23 | 2010-04-29 | Cornell University | A novel anti-viral method |
| US20110230372A1 (en) | 2008-11-14 | 2011-09-22 | Stc Unm | Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia |
| WO2010078569A2 (en) | 2009-01-05 | 2010-07-08 | Stc.Unm | Porous nanoparticle supported lipid bilayer nanostructures |
| US8992984B1 (en) | 2009-10-21 | 2015-03-31 | Stc.Unm | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells |
| US20130017210A1 (en) | 2010-03-17 | 2013-01-17 | Stc.Unm | Display of antibody fragments on virus-like particles of rna bacteriophages |
| US20110300186A1 (en) | 2010-04-14 | 2011-12-08 | Battelle Memorial Institute | Functionalized Nano- and Micro-materials for Medical Therapies |
| CN103687590A (zh) | 2011-04-28 | 2014-03-26 | Stc·Unm公司 | 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法 |
| WO2013012891A1 (en) | 2011-07-19 | 2013-01-24 | Stc. Unm | Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| US20150272885A1 (en) | 2011-10-14 | 2015-10-01 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| WO2013103614A1 (en) | 2011-12-30 | 2013-07-11 | Stc.Unm | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) |
| EP2981611A4 (en) | 2013-04-02 | 2016-11-16 | Stc Unm | ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH |
| WO2014165617A1 (en) | 2013-04-02 | 2014-10-09 | Stc.Unm | Mesoporous alum nanoparticles as universal platform for antigen adsorption, presentation, and delivery |
| WO2015042279A1 (en) | 2013-09-18 | 2015-03-26 | Stc. Unm | Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells |
-
2012
- 2012-04-27 CN CN201280031496.8A patent/CN103687590A/zh active Pending
- 2012-04-27 US US14/113,371 patent/US9579283B2/en active Active
- 2012-04-27 JP JP2014508125A patent/JP2014512409A/ja active Pending
- 2012-04-27 EP EP12776480.1A patent/EP2701686A4/en not_active Withdrawn
- 2012-04-27 WO PCT/US2012/035529 patent/WO2012149376A2/en not_active Ceased
- 2012-04-27 AU AU2012249474A patent/AU2012249474A1/en not_active Abandoned
- 2012-04-27 CA CA2834365A patent/CA2834365A1/en not_active Abandoned
-
2015
- 2015-12-16 US US14/970,998 patent/US10022327B2/en not_active Expired - Fee Related
-
2018
- 2018-07-02 US US16/025,557 patent/US20190091150A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Exosomal targeting and its potential clinical application | |
| US8992984B1 (en) | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells | |
| Dou et al. | Aptamer–drug conjugate: Targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity | |
| Auguste et al. | Triggered release of siRNA from poly (ethylene glycol)-protected, pH-dependent liposomes | |
| Roerig et al. | Standardization approaches for extracellular vesicle loading with oligonucleotides and biologics | |
| US10022327B2 (en) | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same | |
| Wang et al. | Endosomal escape kinetics of mesoporous silica-based system for efficient siRNA delivery | |
| Boado | Blood–brain barrier transport of non-viral gene and RNAi therapeutics | |
| US20170232115A1 (en) | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof | |
| Meissner et al. | Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody | |
| JP2014532071A5 (enExample) | ||
| US20200197536A1 (en) | Porous nanoparticle-supported lipid bilayer delivery of transcriptional gene modulators | |
| Li et al. | Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system | |
| WO2014058179A2 (ko) | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 | |
| R. Beech et al. | Mechanisms for targeted delivery of nanoparticles in cancer | |
| US9211346B2 (en) | Carrier-linked magnetic nanoparticle drug delivery composition and method of use | |
| Khera et al. | Highlighting the potential role of exosomes as the targeted nanotherapeutic carrier in metastatic breast cancer | |
| Herringson et al. | Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid | |
| WO2021234699A1 (en) | MAdCAM-1 POLYPEPTIDES AND USES THEREOF | |
| US20230357353A1 (en) | MAdCAM-1 POLYPEPTIDES AND USES THEREOF | |
| Yue et al. | Methods for Analysis of Extracellular Vesicle Functions | |
| Alfagih | Liposomes for Targeting RNA Interference-Based Therapy in Inflammatory Bowel Diseases | |
| Niculescu et al. | New applications of lipid and polymer-based nanoparticles for nucleic acids delivery. Pharmaceutics. 2021; 13: 2053 | |
| Yang et al. | Nanotechnology in gene delivery: pharmacokinetic and pharmacodynamic perspectives | |
| Nargis | Development of an innovative drug delivery system targeted to adipose vessel utilizing novel nucleic acid aptamer for control of obesity |